drugset / Trial / NCT00544609
Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
NaSingle-groupOpen-labelTreatment
Summary
Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Timeline
- Start
- 2007-12
- Primary completion
- 2010-08
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | — |
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Subject | Sorafenib | Small molecule | 800 mg | — |